COVID-19 testing solutions
We offer various testing solutions that are used across the world today to support fast and trustworthy diagnosis:
- A qualitative molecular rapid detection kit based on real-time fluorescent reverse transcription isothermal amplification and testing of nasopharyngeal swab samples, oropharyngeal swab samples and saliva specimens. This fast assay takes 70 min from sample to result and does not require RNA extraction.
- A qualitative molecular detection kit based on real-time fluorescent reverse transcription amplification and testing of nasopharyngeal swab, nasal swab, nasal aspirates and washes, oropharyngeal swab, BAL, and sputum specimens. This assay gives results within 75 minutes and does require RNA extraction. A rapid version of 3 genes (+/- 40 min) is to be expected in September.
- A high-sensitive antigen assay running on our fully automated chemiluminescent platform, capable of testing both nasopharyngeal swab fluid and saliva samples and giving fast results, in up to 30 minutes.
- A highly sensitive and specific quantitative antibody assay to SARS-CoV-2 Spike (S) RBD protein running on our fully automated CLEIA platform capable of testing both serum and plasma samples and giving fast results, in up to 30 minutes. A quantitative antibody assay to SARS-CoV-2 nucleocapsid protein is also expected in October 2021.
- A lateral flow-based rapid antigen test that does not require any special equipment. This portable single assay device evaluates nasopharyngeal swab fluid, it uses a simple procedure and has a short time to result of only 30 minutes.
Furthermore, thanks to our long-lasting and extensive experience in lung disease testing we also offer associated testing solutions that allow to predict disease severity in patients infected with SARS-CoV-2.
Read more below or contact us today
Insights
[Jan 2022 Update] This scientific literature overview demonstrates the excellent performance of the fully automated nucleocapsid protein antigen assay Lumipulse® G SARS-CoV-2 Ag
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
I...
Webinar: Lumipulse® G KL-6, the biomarker for routinely assessment of epithelial alveolar damage in pulmonary fibrosis and COVID-19
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Japanese authorities have chosen Lumipulse® for nasopharyngeal or saliva-based SARS-CoV-2 antigen testing of passengers at their main international airports
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...